Aytu Bioscience (AYTU) is expected to report First Quarter Fiscal 2021 Results and Provide Business Update on Thursday, November 12, 2020.
In the last earnings report, the company had a net revenue increase of 82% and a 766% year-over-year to $14.9 million. The company also had it’s highest revenue quarter which comes to 2x the entire fiscal 2019 revenue.
In the forth quarter, consumer health net revenue was $6.9 million compared to $3.5 million in the third quarter, respectively Rx net revenue and net loss in the fourth quarter was $7.9 million and -$3.1 million. The company also produced cash equivalents and restricted cash of $48.3 million on June 30, 2020, after fully extinguishing the $15 million Deerfield balloon payment obligation.
Expectations for Aytu Bioscience (AYTU)’s earnings report
Based on our analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.06. The reported EPS for the same quarter last year was $-0.32. While investor sentiment may have decreased, we expect that the price target will trade around $3 minimum in the coming months ahead.
